Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAD Induction in CEBPA Double Mutated AML
NCT04415008Phase 2Active, not recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2020
- Primary completion
- Oct 2026
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of homoharringtonine, cytarabine, daunorubicin in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Jun 2020; status: active, not recruiting.
02
Drugs
homoharringtoninecytarabinedaunorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04415008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04415008.